

STENOCARE A/S achieved its objective of delivering 2,100 treatments during September to December 2018

STENOCARE A/S ("STENOCARE") today announces that the company has delivered 2,200 bottles of medical cannabis oil during September to December 2018 and hence met and exceeded its objective of supplying approx. 2,100 treatments to Danish patients during the period. This objective was communicated in the memorandum that was established in connection to the company's IPO in September/October 2018.

On the 30th of November 2018, STENOCARE announced that the company had received its second batch of medical cannabis oil products, which put STENOCARE on track to meet its objective of supplying approx. 2,100 treatments during 2018. Today, the company announces that they have compiled the deliveries to 2,200 bottles of medical cannabis oil products and thereby achieved its stated objective.

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

"We can gladly announce that we have achieved and exceeded our objective of delivering 2,100 treatments to the Danish market. It feels good to be able to keep delivering on our IPO promises and patient's quality of life, and we will work hard to continue to deliver during 2019."

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

Phone: +45 31770060

E-mail: presse@stenocare.com

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on February 7 2019.

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot programme. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers high quality medical cannabis oil, which is produced by hygienic and high technology cultivation and processing that comply with the strict Danish regulatory requirements. STENOCARE will also develop a separate production facility for the cultivation and production of medical cannabis at the company's premises in Jutland, Denmark.